ARL4D

ARL4D is a myristoylated Arf-family small GTPase that functions as a GTP-dependent signaling scaffold at the plasma membrane, coordinating actin remodeling, cell migration, and microtubule nucleation. In its GTP-bound state, ARL4D recruits cytohesin-2/ARNO to the plasma membrane to activate ARF6, driving actin stress fiber disassembly, endosome-to-plasma-membrane cargo transport, and neurite outgrowth (PMID:17804820, PMID:15049518, PMID:19327349); it also assembles Erk1/2 and Pak1 into a membrane-proximal phosphorylation complex that promotes PDGF-stimulated cell migration, with PI(4,5)P2 binding and Pak1-mediated Ser144 phosphorylation driving ARL4D self-association to amplify signaling (PMID:40309925, PMID:41779780). ARL4D additionally interacts with EB1 via an SxLP motif to promote centrosomal EB1 recruitment and microtubule nucleation (PMID:32755434). TBC1D15 serves as the GAP that converts ARL4D to its GDP-bound form, which translocates to mitochondria in a myristoylation-dependent manner to reduce membrane potential and induce fragmentation (PMID:41709823, PMID:22927989).

1. 2004 Medium

   Establishing that ARL4D nucleotide state dictates its subcellular compartment—GTP-bound at the plasma membrane versus GDP-bound at endosomes—and that this toggle controls transferrin receptor trafficking, providing the first functional readout for ARL4D's GTPase cycle.

   Evidence Immunocytochemistry with constitutively active (Q80L) and dominant-negative (T35N) ARL4D mutants, transferrin receptor localization assay

   PMID:15049518

   Open questions at the time

   • Single imaging-based method without biochemical confirmation of GTP loading
   • Endogenous ARL4D localization not assessed
   • Mechanism of endosome-to-PM transport effect unclear
2. 2007 High

   Identifying cytohesin-2/ARNO as the first direct effector of GTP-bound ARL4D and establishing a linear ARL4D→cytohesin-2→ARF6 activation cascade that controls actin remodeling and cell migration, thus defining ARL4D's primary signaling axis.

   Evidence Co-immunoprecipitation, GTP-dependent binding assays, dominant-active/inactive mutants, siRNA knockdown, ARF6-GTP pull-down, and cell migration assay in HeLa cells

   PMID:17804820

   Open questions at the time

   • GAP and GEF for ARL4D itself unidentified
   • Whether ARL4D acts on cytohesins other than ARNO not tested
3. 2008 Medium

   Revealing that ARL4D protein abundance is regulated post-transcriptionally via the Akt/mTOR axis, linking upstream growth-factor signaling to ARL4D expression control.

   Evidence Western blot in isogenic PTEN-mutant glioblastoma lines, rapamycin treatment, polysomal fractionation

   PMID:18240926

   Open questions at the time

   • Direct mTOR-regulated translational element on ARL4D mRNA not mapped
   • Functional consequence of ARL4D upregulation in PTEN-null cells not tested
4. 2009 Medium

   Extending the ARL4D→cytohesin-2→ARF6 pathway to a physiological morphogenesis outcome—neurite outgrowth—and demonstrating that ARL4D is both necessary and sufficient for this process.

   Evidence siRNA knockdown, constitutively active ARL4D overexpression, cell-permeable competing peptide, SecinH3 inhibitor, and isoform-specific ARF knockdown in neuronal differentiation model

   PMID:19327349

   Open questions at the time

   • In vivo neural development phenotype not examined
   • Endogenous regulation of ARL4D during differentiation not characterized
5. 2012 Medium

   Demonstrating that GDP-bound ARL4D translocates to mitochondria in a myristoylation-dependent manner and impairs mitochondrial membrane potential and morphology, establishing a second, nucleotide-state-specific functional compartment distinct from its plasma membrane role.

   Evidence Subcellular fractionation, confocal immunofluorescence, JC-1 membrane potential assay, domain deletion mutants of ARL4D(T35N)

   PMID:22927989

   Open questions at the time

   • Mitochondrial target/receptor unknown
   • Whether endogenous ARL4D reaches mitochondria under physiological conditions not shown
   • Mechanism linking ARL4D to fission machinery undefined
6. 2018 Medium

   Placing ARL4D as a downstream effector of PD-L1 signaling in CD8 T cells that limits IL-2 production and Akt phosphorylation, defining a new immunological function where ARL4D restrains T cell effector expansion.

   Evidence Arl4d knockout mice, in vivo viral infection, IL-2 ELISA, Akt phosphorylation Western blot, flow cytometry

   PMID:30382149

   Open questions at the time

   • Direct molecular target of ARL4D in T cells not identified
   • Whether ARL4D's GTPase activity is required for this immune phenotype not tested
7. 2020 High

   Identifying EB1 as a GTP-dependent interactor of ARL4D through an SxLP motif, and showing that ARL4D promotes centrosomal EB1 recruitment and microtubule nucleation, thus extending ARL4D function beyond actin to the microtubule cytoskeleton.

   Evidence Reciprocal co-IP, GST pulldown, SxLP motif mutagenesis, siRNA depletion, live-cell microtubule nucleation assay, proximity ligation assay

   PMID:32755434

   Open questions at the time

   • Physiological stimulus that activates ARL4D at centrosomes unknown
   • Whether ARL4D and EB1 interaction is cell-cycle regulated not tested
8. 2025 High

   Establishing ARL4D as a scaffolding platform that co-recruits Erk1/2 and Pak1 to the plasma membrane, enabling Erk-mediated Pak1 phosphorylation and PDGF-driven cell migration—expanding ARL4D from a GTPase-cascade activator to a kinase-organizing scaffold.

   Evidence Reciprocal co-IP, plasma membrane fractionation, Pak1 phosphorylation assays, dominant-mutant/knockdown approaches, cell migration assay

   PMID:40309925

   Open questions at the time

   • Whether scaffold function requires simultaneous ARF6 activation not tested
   • Stoichiometry of the ARL4D–Erk–Pak1 complex not determined
9. 2026 High

   Revealing that PI(4,5)P2 binding and Pak1-mediated Ser144 phosphorylation cooperatively drive GTP-dependent ARL4D self-association at the plasma membrane, creating a positive-feedback loop that amplifies Pak1 signaling and cell migration.

   Evidence In vitro lipid-binding assay, co-IP, phosphomimetic/phosphodeficient mutants, AlphaFold-guided mutagenesis, FRAP, Pak1 kinase assay, forced-dimerization rescue

   PMID:41779780

   Open questions at the time

   • Oligomeric state (dimer vs. higher-order cluster) not resolved biophysically
   • Whether self-association also affects EB1 or cytohesin-2 pathways untested
10. 2026 High

    Identifying TBC1D15 as the GAP for ARL4D, showing that TBC1D15-catalyzed GTP hydrolysis promotes ARL4D translocation to mitochondria under serum starvation and thereby closes the regulatory cycle governing ARL4D nucleotide state and compartmental switching.

    Evidence Co-IP mapping TBC domain interaction, in vitro GAP assay, siRNA knockdown of TBC1D15, GTP-Arl4D pull-down, mitochondrial fractionation and immunofluorescence

    PMID:41709823

    Open questions at the time

    • GEF for ARL4D remains unidentified
    • Physiological signals that regulate TBC1D15 activity toward ARL4D not defined

• The GEF that activates ARL4D, the mitochondrial receptor for GDP-bound ARL4D, and the structural basis of ARL4D self-association all remain unknown, as does how the plasma membrane (actin/migration) and centrosomal (microtubule nucleation) functions of ARL4D are coordinated in space and time.
• No GEF identified
• Mitochondrial receptor/tether for GDP-ARL4D unknown
• No high-resolution structure of ARL4D oligomer
• Coordination between ARF6, Pak1/Erk, and EB1 signaling arms not addressed